BioPharma Terug naar discussie overzicht

ampio pharma + 20%

1. [verwijderd] 6 december 2016 16:55

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ik weet niet waarom die zo omhoog schiet, geen nieuws te vinden maar schiet dus zomaar even van slot gisteren op 0,80 omhoog en heeft 2x de 1 dollar aangetikt vandaag.
   
   ampiopharma.com/
2. [verwijderd] 6 december 2016 17:00

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.desotoedge.com/stocks/ampio-pharm...
   
   Ampio Pharmaceuticals, Inc. (AMPE) Reviewed By Analysts
   By Ashley Brown / in Stocks / on Tuesday, 06 Dec 2016 11:49 AM / 0 Comments
   Stock market analysts watching Ampio Pharmaceuticals, Inc. (AMPE) have recently changed their ratings on the stock. The latest reports which are outstanding on Tuesday 6th of December state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
   
   Latest stock market analyst ratings:
   
   
   08/22/2014 – Ampio Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Jefferies. They now have a USD 5 price target on the stock.
   
   08/21/2014 – Ampio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Aegis Capital.
   
   05/08/2014 – Citigroup began new coverage on Ampio Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 21 price target on the stock.
   
   Ampio Pharmaceuticals, Inc. has a 50 day moving average of 0.72 and a 200 day moving average of 1.42. The stock’s market capitalization is 45.97M, it has a 52-week low of 0.59 and a 52-week high of 4.32.
   
   The share price of the company (AMPE) was up +4.39% during the last trading session, with a high of 0.82 and the volume of Ampio Pharmaceuticals, Inc. shares traded was 318414.
   
   Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
3. [verwijderd] 6 december 2016 17:08

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ook de 1,048 aangetikt ruim 25%
4. [verwijderd] 21 september 2020 14:17

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   AMPE trial results
   
   10 SARS-CoV-2 patients were suffering severe oxygen shortage
   
   5 patients treated with Ampion were all cured and went home
   
   5 patients treated with Remdesivir and SOC, 1 Died, 1 still in hospital, 3 went home
   
   Ampion clearly did 40% better.
5. [verwijderd] 21 september 2020 14:25

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   ampalizer.info/